thiotepa has been researched along with Cancer of Eye in 19 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thiotepa, busulfan and cyclophosphamide-based intensive chemotherapy is an effective treatment for refractory and recurrent primary central nervous system lymphoma in chemosensitive patients up to 65 years of age." | 9.16 | Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. ( Bouabdallah, K; Choquet, S; Damaj, G; Delgadillo, D; Dupriez, B; Fourme, E; Ghesquières, H; Gonzalez, A; Hoang-Xuan, K; Houillier, C; Leblond, V; Soussain, C; Taillandier, L; Vargaftig, J, 2012) |
| "Thiotepa, busulfan and cyclophosphamide-based intensive chemotherapy is an effective treatment for refractory and recurrent primary central nervous system lymphoma in chemosensitive patients up to 65 years of age." | 5.16 | Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. ( Bouabdallah, K; Choquet, S; Damaj, G; Delgadillo, D; Dupriez, B; Fourme, E; Ghesquières, H; Gonzalez, A; Hoang-Xuan, K; Houillier, C; Leblond, V; Soussain, C; Taillandier, L; Vargaftig, J, 2012) |
| "Melphalan was a key drug in all patients, and was administered in combination with other agents such as cisplatin, cyclophosphamide, carboplatin or thiotepa." | 1.33 | A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. ( Higa, T; Hosono, A; Kaneko, A; Kawamoto, H; Makimoto, A; Matsubara, H; Murayama, S; Ohira, M; Sakiyama, S; Sumi, M; Takaue, Y; Takayama, J, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (36.84) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Soussain, C | 4 |
| Choquet, S | 2 |
| Fourme, E | 2 |
| Delgadillo, D | 1 |
| Bouabdallah, K | 1 |
| Ghesquières, H | 1 |
| Damaj, G | 1 |
| Dupriez, B | 2 |
| Vargaftig, J | 1 |
| Gonzalez, A | 1 |
| Houillier, C | 1 |
| Taillandier, L | 2 |
| Hoang-Xuan, K | 4 |
| Leblond, V | 3 |
| TUKAMOTO, K | 1 |
| KOJIMA, S | 1 |
| BURNS, RP | 1 |
| BEIGHLE, R | 1 |
| Lai, R | 1 |
| Abrey, LE | 1 |
| Rosenblum, MK | 1 |
| DeAngelis, LM | 2 |
| Levy, V | 2 |
| Matsubara, H | 1 |
| Makimoto, A | 1 |
| Higa, T | 1 |
| Kawamoto, H | 1 |
| Sakiyama, S | 1 |
| Hosono, A | 1 |
| Takayama, J | 1 |
| Takaue, Y | 1 |
| Murayama, S | 1 |
| Sumi, M | 1 |
| Kaneko, A | 1 |
| Ohira, M | 1 |
| Popovic, MB | 1 |
| Diezi, M | 1 |
| Kuchler, H | 1 |
| Abouzeid, H | 1 |
| Maeder, P | 1 |
| Balmer, A | 1 |
| Munier, FL | 1 |
| Witz, F | 1 |
| Casasnovas, O | 1 |
| Souleau, B | 1 |
| Taksin, AL | 1 |
| Gisselbrecht, C | 1 |
| Jaccard, A | 1 |
| Omuro, A | 1 |
| Sanson, M | 1 |
| Janvier, M | 1 |
| Kolb, B | 1 |
| Zini, JM | 1 |
| Seregard, S | 1 |
| Kock, E | 1 |
| af Trampe, E | 1 |
| Freilich, RJ | 1 |
| Delattre, JY | 2 |
| Monjour, A | 1 |
| Sandor, V | 1 |
| Stark-Vancs, V | 1 |
| Pearson, D | 1 |
| Nussenblat, R | 1 |
| Whitcup, SM | 1 |
| Brouwers, P | 1 |
| Patronas, N | 1 |
| Heiss, J | 1 |
| Jaffe, E | 1 |
| deSmet, M | 1 |
| Kohler, D | 1 |
| Simon, R | 1 |
| Wittes, R | 1 |
| Suzan, F | 1 |
| Cassoux, N | 1 |
| Azar, N | 1 |
| Belanger, C | 1 |
| Achour, E | 1 |
| Ribrag, V | 1 |
| Gerber, S | 1 |
| Heath, JA | 1 |
| Broxson, EH | 1 |
| Dole, MG | 1 |
| Filippa, DA | 1 |
| George, D | 1 |
| Lyden, D | 1 |
| Dunkel, IJ | 1 |
| Morrison, VA | 1 |
| Weinshel, EL | 1 |
| Luikart, SD | 1 |
| Sellami, M | 1 |
| Weil, M | 1 |
| Maral, J | 1 |
| Auclerc, G | 1 |
| Dhermy, P | 1 |
| Aron-Rosa, D | 1 |
| Jacquillat, C | 1 |
| Lisichkina-Nifantova, TP | 1 |
| Iguchi, K | 1 |
| Ikeda, K | 1 |
| Nakamura, T | 1 |
| Toda, T | 1 |
| Akiyoshi, T | 1 |
| Kotelianskiĭ, EO | 1 |
| Lavergne, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841] | Phase 3 | 250 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
2 reviews available for thiotepa and Cancer of Eye
| Article | Year |
|---|---|
Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cranial Irradia | 2004 |
[Some current problems in the therapy of intraocular tumors].
Topics: Cryosurgery; Eye Neoplasms; Female; Humans; Laser Therapy; Male; Melanoma; Methods; Neoplasm Metasta | 1971 |
5 trials available for thiotepa and Cancer of Eye
| Article | Year |
|---|---|
Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla | 2012 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cent | 1996 |
Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytar | 1998 |
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; C | 2001 |
12 other studies available for thiotepa and Cancer of Eye
| Article | Year |
|---|---|
[On local treatment of conjunctival cysts with Tespamin].
Topics: Conjunctiva; Conjunctival Diseases; Cysts; Eye Neoplasms; Humans; Thiotepa | 1963 |
Effects of triethylenethiophos phoramide on the carrageenin granuloma of the guinea pig cornea.
Topics: Carrageenan; Cornea; Eye Neoplasms; Granuloma; Guinea Pigs; Polysaccharides; Thiotepa | 1962 |
[Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla | 2004 |
A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carboplatin; Central Nervous Syst | 2005 |
Trilateral retinoblastoma with suprasellar tumor and associated pineal cyst.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Cysts; Child; Cy | 2007 |
Intravitreal chemotherapy for recurrent retinoblastoma in an only eye.
Topics: Combined Modality Therapy; Eye Neoplasms; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; | 1995 |
Epstein-Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue.
Topics: Acyclovir; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Ph | 2002 |
Corynebacterium JK: a new pathogen in ventriculostomy infections.
Topics: Corynebacterium Infections; Cross Infection; Dexamethasone; Drug Delivery Systems; Eye Neoplasms; Hu | 1991 |
[Adjuvant chemotherapy of intraocular malignant melanoma. Apropos of 20 cases].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1985 |
[Thio-tepa (triethylamine thiophosphamide) in complex treatment of patients with melanoblastoma of the uveal tract].
Topics: Animals; Eye Neoplasms; Humans; Melanoma; Neoplasms, Experimental; Rabbits; Thiotepa; Transplantatio | 1972 |
[Contineous intra-arterial perfusion of carcinostatic drugs for retinoblastoma].
Topics: Child, Preschool; Eye Neoplasms; Female; Humans; Infant; Injections, Intra-Arterial; Male; Methotrex | 1967 |
[Clinical and experimental study of the action of triethylene-thiophosphoramide on corneal vascularization].
Topics: Cornea; Eye Diseases; Eye Neoplasms; Thiotepa; Vascular Diseases | 1967 |